AMARILLO, Texas, Nov. 7 /PRNewswire/ -- Amarillo Biosciences, Inc.
(OTC Bulletin Board: AMAR) announced today that it has exclusively engaged
Hunter Wise Financial Group, LLC to advise the biopharmaceutical company on
shareholder value creation options. Working with Hunter Wise, Amarillo will
assess various new strategic business alternatives including corporate
development, corporate finance and capital placement transactions.
In making the announcement, Dr. Joseph M. Cummins, Amarillo's chairman,
President and Chief Executive Officer, said, "We are very pleased to be
working with an investment banking firm of Hunter Wise's caliber, experience
and expertise. We believe this relationship will allow us to raise additional
capital, broaden our exposure to a wider audience and ultimately create
increased shareholder value."
Daniel J. Merkle, managing director, Hunter Wise Financial Group,
underscored the potential of this relationship. "It is our strong belief that
the inherent value of many small-cap public companies is sadly overlooked by
the market. Amarillo, which holds an exciting portfolio of proprietary
biopharmaceuticals with outstanding prospects for widespread immunology
therapy application, is typical of this unfortunate market oversight. Based
on our experience in creating shareholder value for this type of company, we
intend to leverage the company's exceptional potential to assist it in
achieving its financial goals."
Amarillo simultaneously announced multiple developments related to its
Phase III, U.S. clinical program in Sjogren's syndrome. "Amarillo is
aggressively pursuing its Phase III clinical trial in Sjogren's syndrome,
which is showing significant progress. We are analyzing data from the second
phase of the Phase III clinical trials using oral interferon, which we expect
to complete by year-end. We also are continuing the development of plans and
activities related to clinical trial developments in Behcet's disease and
hepatitis C. All these developments, combined with this new partnership, are
very positive for our investors," Cummins said.
Hunter Wise Financial Group, LLC, based in Newport Beach, Calif., has
offices in Scottsdale, Ariz. and Boca Raton, Florida, as well as a network of
14 international offices worldwide. Hunter Wise provides Fortune 500-type
corporate finance services exclusively designed for often-overlooked small- to
medium-sized public companies, as well as selected middle-market, privately
held businesses. Hunter Wise specializes in institutional finance; mergers,
acquisitions and divestitures; financial advisory services; seller
representations; strategic alternative advisories; buyer representations;
management buyouts; recapitalizations; corporate valuations; defensive
advisories; employee stock ownership plans and international transactions.
For additional company information, visit the Web site at http://www.amarbio.com, or
call Dan Merkle at (800) 830-5333.
Amarillo Biosciences, founded in 1984, is a pioneer in the development of
low-dose orally administered interferon alpha as a treatment for a variety of
conditions, including Sjogren's syndrome, fibromyalgia syndrome, Behcet's
disease, hepatitis B and C and opportunistic infections in patients who are
HIV positive.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the Company's other product
candidates and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission. In particular, see Item 1.
Description of Business of the Company's Form 10-KSB for the year ended
December 31, 1999.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html or fax,
800-758-5804, ext. 118055
CONTACT:
Kathleen Kelleher of Amarillo Biosciences,
Inc., 806-376-1741 ext. 15, or kkelleher@amarbio.com; or Dianne
Seeber of Hunter Wise Financial Group/Rodheim Marketing Group,
800-576-5101 ext. 11, or dianne@rodheim-marketing.com, for
Amarillo Biosciences, Inc.
|
